Eli Lilly Stock Surges on Successful Weight-Loss Drug Trial

BTCC / BTCC Square / Global Cryptocurrency /

Author:

Release Time:

2025-08-27 03:06:01

BTCCSquare news:

Eli Lilly's stock soared nearly 6% on Tuesday, outpacing the S&P 500's modest 0.4% gain, following promising phase 3 trial results for its oral weight-loss drug orforglipron. The medication demonstrated significant efficacy, with participants losing an average of 10.5% of their body weight over 72 weeks, compared to 2.2% for the placebo group.

The drug also showed positive effects on blood sugar levels, positioning it as a potential blockbuster in the cardiometabolic health market. Eli Lilly now plans to expedite regulatory submissions to the FDA and other global agencies, aiming to address high patient demand for effective weight-loss treatments.

By:

Log in to Reply

Defense Sector Could Be Next for Government Equity Deals After Intel, Says Lutnick

Articles on this site are sourced from public networks or curated by AI for informational purposes only and do not represent BTCC’s views. Original rights belong to the respective authors. For copyright concerns, please contact [email protected]. BTCC assumes no liability for the accuracy, timeliness, or completeness of this information, and disclaims all liability arising from reliance on such content. This content is for reference only and should not be taken as investment, legal, or commercial advice.